Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
Geron (GERN) has scheduled the release of its fourth quarter and full-year 2024 financial results before market opening on Wednesday, February 26, 2025. The company will host a conference call at 8:00 a.m. Eastern Time on the same day to discuss financial results and business highlights.
The conference call will include a related presentation and will be accessible via webcast through the company's website. An archive of the webcast will remain available for 30 days following the event. Interested participants can register for the webcast through a provided registration link.
Geron (GERN) ha programmato la pubblicazione dei sui risultati finanziari del quarto trimestre e dell'anno completo 2024 prima dell'apertura del mercato il mercoledì 26 febbraio 2025. L'azienda organizzerà una conference call alle 8:00 a.m. ora orientale dello stesso giorno per discutere i risultati finanziari e i principali eventi aziendali.
La conference call includerà una presentazione correlata e sarà accessibile tramite webcast attraverso il sito web dell'azienda. Un'archivio del webcast sarà disponibile per 30 giorni dopo l'evento. I partecipanti interessati possono registrarsi per il webcast tramite un link di registrazione fornito.
Geron (GERN) ha programado la publicación de sus resultados financieros del cuarto trimestre y del año completo 2024 antes de la apertura del mercado el miércoles 26 de febrero de 2025. La compañía llevará a cabo una conferencia telefónica a las 8:00 a.m. hora del Este el mismo día para discutir los resultados financieros y los aspectos destacados del negocio.
La conferencia telefónica incluirá una presentación relacionada y será accesible a través de un webcast en el sitio web de la compañía. Un archivo del webcast estará disponible durante 30 días después del evento. Los participantes interesados pueden registrarse para el webcast a través de un enlace de registro proporcionado.
Geron (GERN)은 2024년 4분기 및 연간 재무 결과를 2025년 2월 26일 수요일 시장 개장 전에 발표할 예정입니다. 회사는 같은 날 동부 표준시 기준 오전 8시에 재무 결과 및 비즈니스 하이라이트에 대해 논의하는 컨퍼런스 콜을 개최합니다.
컨퍼런스 콜에는 관련 프레젠테이션이 포함되며 회사 웹사이트를 통해 웹캐스트로 접근할 수 있습니다. 웹캐스트의 아카이브는 이벤트 이후 30일 동안 이용 가능합니다. 관심 있는 참가자는 제공된 등록 링크를 통해 웹캐스트에 등록할 수 있습니다.
Geron (GERN) a prévu de publier ses résultats financiers du quatrième trimestre et de l’année complète 2024 avant l’ouverture des marchés le mercredi 26 février 2025. L’entreprise organisera une conférence téléphonique à 8h00, heure de l'Est, le même jour pour discuter des résultats financiers et des points forts de l'entreprise.
La conférence téléphonique inclura une présentation associée et sera accessible par webdiffusion via le site web de l'entreprise. Un enregistrement de la webdiffusion sera disponible pendant 30 jours après l’événement. Les participants intéressés peuvent s'inscrire à la webdiffusion via un lien d'inscription fourni.
Geron (GERN) hat die Veröffentlichung seiner finanziellen Ergebnisse für das vierte Quartal und das Gesamtjahr 2024 vor Markteröffnung am Mittwoch, den 26. Februar 2025 angesetzt. Das Unternehmen wird am selben Tag um 8:00 Uhr Eastern Time eine Telefonkonferenz abhalten, um die finanziellen Ergebnisse und Geschäftshighlights zu besprechen.
Die Telefonkonferenz wird eine dazugehörige Präsentation umfassen und über einen Webcast auf der Website des Unternehmens zugänglich sein. Ein Archiv des Webcasts wird 30 Tage nach der Veranstaltung verfügbar bleiben. Interessierte Teilnehmer können sich über einen bereitgestellten Registrierungslink für den Webcast anmelden.
- None.
- None.
A live webcast of the conference call and related presentation will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.
Participants may access the webcast by registering online using the following link, https://events.q4inc.com/attendee/332361629
About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250203545163/en/
Aron Feingold
Vice President, Investor Relations and Corporate Communications
Kristen Kelleher
Associate Director, Investor Relations and Corporate Communications
investor@geron.com
media@geron.com
Source: Geron Corporation
FAQ
When will Geron (GERN) release its Q4 and full-year 2024 earnings?
What time is Geron's (GERN) Q4 2024 earnings call?
How can I access Geron's (GERN) Q4 2024 earnings webcast?
How long will Geron's (GERN) Q4 2024 earnings webcast be available for replay?
